Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Chocolate may boost brain power
By Megan Rauscher Wed May 24, 3:02 PM ET
NEW YORK (Reuters Health) - Chocolate lovers rejoice. A new study hints that eating milk chocolate may boost brain function.
ADVERTISEMENT
"Chocolate contains many substances that act as stimulants, such as theobromine, phenethylamine, and caffeine," Dr. Bryan Raudenbush from Wheeling Jesuit University in West Virginia noted in comments to Reuters Health.
"These substances by themselves have previously been found to increase alertness and attention and what we have found is that by consuming chocolate you can get the stimulating effects, which then lead to increased mental performance."
To study the effects of various chocolate types on brain power, Raudenbush and colleagues had a group of volunteers consume, on four separate occasions, 85 grams of milk chocolate; 85 grams of dark chocolate; 85 grams of carob; and nothing (the control condition).
After a 15-minute digestive period, participants completed a variety of computer-based neuropsychological tests designed to assess cognitive performance including memory, attention span, reaction time, and problem solving.
"Composite scores for verbal and visual memory were significantly higher for milk chocolate than the other conditions," Raudenbush told Reuters Health. And consumption of milk and dark chocolate was associated with improved impulse control and reaction time.
Previous research has shown that some nutrients in food aid in glucose release and increased blood flow, which may augment cognitive performance. The current findings, said Raudenbush, "provide support for nutrient release via chocolate consumption to enhance cognitive performance."
beachgal,
A while back, there were some posts from Marty Marion. (Or so he claimed to be.) So a few weeks ago, I sent an e-mail to him with a few questions about when the phase 3 would start and where. But there has been no response. I am sure they have a policy that such news should be in a public release, but it has been a bit quiet for me as well.
ScaryStocks
That was fast. But they did say on the conference call that they wanted to complete the sale as soon as possible.
I listened to the call last night. And it was clear to me that this aquisition was well thought out. The experience of the Alamo sales force will help a lot when Neurodex is approved and launched to the market.
We would have had a better reaction from the market, if the market wasn't in such a funk this week. But given the negative market sentiment in general, the positive movement of AVNR today and yesterday is encouraging. IMO.
ScaryStocks
Great point eb0783. With this aquisition, Avanir now has fifty or so sales representatives already on the street.
This is a great move for future sales of Neurodex. IMO.
ScaryStocks
I agree with Randy.
Lets stop cluttering the board up with idle chit chat regarding whether it is going up today or down today...
Tons of these types of posts make it more difficult for new investors to find posts that have good information.
I urge everyone to post only useful and relevant information. Yes, we are in a quite period. But be patient.
ScaryStocks
Analyst's top rated stocks including AVNR.
I saw this on Biotech Values Board.
http://online.wsj.com/article/BT-CO-20060509-001847.html?mod=wsjcrmain
Form 8-K for AVANIR PHARMACEUTICALS
8-May-2006
Entry into a Material Definitive Agreement, Results of Operations and Fina
Item 1.01 Entry into a Material Definitive Agreement.
On May 4, 2006, Avanir Pharmaceuticals (the "Company") entered into an employment agreement with Michael J. Puntoriero. The disclosure set forth below under Item 5.01 relating to this agreement is incorporated herein by reference.
On May 5, 2006, the Company entered into a lease for office space in Orange County, California (the "Lease"). The disclosure set forth below under Item 2.05 relating to the Lease is incorporated herein by reference.
Item 2.02 Results of Operations and Financial Condition.
On May 8, 2006, the Company issued a press release announcing the results of operations for the quarter and six months ended March 31, 2006. A copy of this press release is filed herewith as Exhibit 99.1.
The information set forth under Item 2.02 and in Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.
The disclosure set forth below under Item 2.05 relating to the Lease is incorporated herein by reference.
Item 2.05 Costs Associated with Exit or Disposal Activities.
On May 4, 2006, the Company's Board of Directors authorized a space restructuring plan and the relocation of the Company's commercial and general and administrative operations. The Company currently occupies three laboratory buildings in San Diego, California, two of which are substantially underutilized and do not fit the Company's long-term commercialization plans. In an effort to address this underutilization and to lower the Company's long-term occupancy costs, the Board of Directors approved a plan to consolidate operations into one building in San Diego, with plans to sublease the two remaining buildings, and to move commercial and general and administrative operations to new office space in Orange County, California.
In connection with the consolidation of operations and relocation activity, the Company expects to record aggregate charges of approximately $2.0 million to $2.5 million through the quarter ending December 31, 2006, which consist of employee-related expenses, costs related to the cease use and subsequent sublease of two laboratory buildings and relocation expense. Due to significantly improved utilization of existing space and sublease of excess space, the Company expects to save approximately $1.0 million in the aggregate in operating activities over a three-year period, net of restructuring costs. Capital expenditures related to purchases of new laboratory equipment and leasehold improvements are projected to amount to approximately $1.5 million.
On May 5, 2006, the Company entered into a lease for the new Orange County facilities, which will consist initially of approximately 11,000 square feet of office space, increasing to 17,000 square feet in the second quarter of 2007, leased for an initial term of five years. The aggregate minimum payments over the initial term of the lease are expected to be approximately $2.8 million.
Item 5.01 Changes in Control of Registrant.
On May 4, 2006, the Board of Directors appointed Michael Puntoriero as the Company's Senior Vice President, Finance. Prior to joining Avanir, Mr. Puntoriero spent over 20 years with Arthur Andersen LLP, including positions as audit partner, head of the Orange County, California audit practice and later as Managing Partner of the Orange County office. Following Arthur Andersen, Mr. Puntoriero has held senior executive positions with Fleetwood Enterprise, Inc. and has served as Executive Vice President and Chief Financial Officer of First Consulting Group, Inc. Mr. Puntoriero earned his Bachelor of Science degree in Accounting from California State University, Northridge and his Masters of Business Administration from the University of Southern California. Mr. Puntoriero is a licensed certified public accountant in California and has completed the Director Training and Certification Program at the UCLA Anderson School of Management. Effective as of May 15, 2006, Mr. Puntoriero will become the Company's Chief Financial Officer. At that time, Gregory P. Hanson, who is currently the Company's Vice President and Chief Financial Officer, will assume the new position of Vice President and Chief Accounting Officer.
Pursuant to the employment agreement with Mr. Puntoriero, he will serve in an at-will capacity, with an initial annual base salary of $300,000. Upon the commencement of employment, Mr. Puntoriero was paid a signing bonus of $40,000, which must be repaid in certain circumstances if Mr. Puntoriero does not remain employed by the Company for one year. Mr. Puntoriero is entitled to receive an annual bonus commencing in October 2006 in a target amount equal to 35% of his base salary (pro rated for 2006). The actual amount of Mr. Puntoriero's annual bonus awards will be determined by the Compensation Committee.
Pursuant to the employment agreement, Mr. Puntoriero was also awarded 10,000 shares of restricted Class A common stock (the "Restricted Stock"), which will vest with respect to one-third of the shares on the first anniversary of his employment with the Company and then with respect to one-twelfth of the shares quarterly thereafter, so that the shares will be fully vested upon the third anniversary of Mr. Puntoriero's employment with the Company. If Mr. Puntoriero's employment terminates for "Cause," or without "Good Reason" (as such terms are defined in the employment agreement), the Company may reacquire the unvested shares at a nominal purchase price ($0.001 per share).
Additionally, Mr. Puntoriero was awarded an inducement option to purchase up to 100,000 shares of Class A common stock at an exercise price equal to the fair market value of the underlying shares on the date of grant (the "Initial Option"). The Initial Option has a ten-year term and will be subject to a four-year vesting schedule, vesting with respect to 25% of the underlying shares one year after the grant and the with respect to the remaining shares in 12 equal installments on a quarterly basis thereafter. The Initial Option will be granted as an inducement option outside of the Company's existing equity incentive plans, but will be subject to the general terms and conditions of the Company's 2005 Equity Incentive Plan. Commencing in November 2006, Mr. Puntoriero will be eligible to receive an annual target option grant equal to the greater of 25,000 shares of Class A common stock or the amount set for other Senior Vice Presidents of the Company (the "Annual Option"), with an exercise price equal to the fair market value of the underlying shares on the date of grant, subject to a four-year vesting schedule, vesting with respect to 25% of the underlying shares one year after the grant and vesting with respect to the remaining shares in 12 equal installments on a quarterly basis thereafter. Each Annual Option will be subject to the terms and conditions of the Company's equity incentive plans. The size of the option grants shall be established by the Compensation Committee and may be larger or smaller than the target size, depending on the satisfaction of performance criteria (which may include Company overall performance criteria) established by the President and Chief Executive Officer or Compensation Committee of the Board. The Annual Option granted in November 2006 will be prorated from the Commencement Date.
Mr. Puntoriero will be eligible to participate in Company benefit plans on the same basis and terms as are applicable to other Senior Vice Presidents of the Company and the Company will either provide Mr. Puntoriero with term life insurance in the amount of $2.5 million or reimburse him for the premium costs of such a policy.
If Mr. Puntoriero is terminated without Cause, or if he resigns for Good Reason, then he will be entitled to (i) severance pay in an amount equal to nine months base salary and an amount equal to the greater of (x) 26.25% of the base salary or (y) 75% of the annual last bonus, if any, paid to Mr. Puntoriero, and (ii) accelerated vesting of the Restricted Stock.
On May 8, 2006, the Company issued a press release announcing the appointment of Mr. Puntoriero. A copy of this press release is filed herewith as Exhibit 99.2 and the text of which is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
Exhibit Description
99.1 Press release, dated May 8, 2006.
99.2 Press release, dated May 8, 2006.
I didn't think that the market would react to yesterdays news like this.
Volume was over 13 million compared to the average 1 million.
News regarding increased capacity could really send this higher...
Hopefully soon.
Good luck.
Crazy day...
Down to 10.15 in the AM
Back up to 11.23 in the PM
Then finished down a bit.
I would be interested in Dr. Bio's views on the recent slide of the PPS.
Bravo! Foods Announces Addition to Management Team
Tuesday May 2, 8:30 am ET
NORTH PALM BEACH, Fla., May 2 /PRNewswire-FirstCall/ -- Bravo! Foods International Corp. (OTC Bulletin Board: BRVO - News), a brand development and marketing company that manufactures, promotes and distributes vitamin- fortified, flavored milk drinks and other beverages, announced today that Mr. Jack Shea will be named Director of Business Development - Allied Brands. In this newly created position Mr. Shea will be responsible for the development and sales of all non-dairy beverages including teas and flavored waters.
Mr. Shea has over thirty years of experience in sales and marketing in the soft drink and beverage industry. He has worked primarily with development stage companies. His experience includes new product research, strategic planning, advertising, distribution as well as propriety packaging design for newly created beverage brands. Mr. Shea's accomplishments include the brand development of several non dairy beverages.
Roy Warren, Bravo!'s Chief Executive Officer commented, "The hiring of Mr. Shea represents a commitment by Bravo! to focus on the development of its non- dairy beverage business. Jack's thirty years of experience in developing beverage brands fits in well with Bravo!'s future growth strategy to participate in the 'better for you', dairy and non-dairy, beverage arena. We are extremely pleased to have Jack as a member of our management team."
Mike Edwards, Bravo!'s Chief Revenue Officer commented, "With Mr. Shea's experience in building distribution networks, Bravo! will be well positioned to achieve further significant penetration and resulting revenue growth across all beverage channels."
Mr. Shea commented, "I look forward to developing the non-dairy beverage business for Bravo! and am excited to be a member of the company's management team and about the potential growth opportunity for non-dairy based products at Bravo!."
About Bravo! Foods International
Bravo! Foods International Corp. develops, brands, markets, distributes and sells nutritious, flavored milk products throughout the 50 United States, Great Britain and various Middle Eastern countries. Bravo!'s products are available in the United States and internationally through production agreements with regional aseptic milk processors and are currently sold under the brand names Slammers® and Bravo!(TM). Bravo!'s Slammers® products are available nationwide in popular chains such as: 7-Eleven, A&P, Dutch Farms, Giant Food Stores, Jewel, Kings, Pathmark, Safeway, Sam's Club, Shaw's, ShopRite, Speedway, SuperTarget, Unified, Waldbaums and Walgreens.
Many of Bravo! Foods' Slammers® lines of shelf-stable, single-serve milk drinks are co-branded through exclusive partnerships with Masterfoods, a division of Mars Incorporated.
On November 1, 2005, Coca-Cola Enterprises, Inc. began distribution of the Slammers® Masterfoods line, as well as the Bravo!'s Slim Slammers® and Pro Slammers(TM) products, under a Master Distribution Agreement with Bravo!
beachgal:
The First Phase III was done at "8 clinical investigation sites" according to some of the old news releases.
I am not sure where the next part of the Phase III will be done, but I have sent an inquiry to the company. When I hear something, I will let you know.
ScaryStocks
Beachgal:
I remember from one of the interviews, Chas Radovich saying something about the trail starting with the beginning of allergy season (April).
But Randy also provided some info recently that suggested June.
I may be wrong on the dates, but you said not to look it up...LOL
ScaryStocks
Soaring Pollen Counts Spur Worst Allergy Season in Years
By E.J. Mundell
HealthDay Reporter
THURSDAY, April 27 (HealthDay News) -- April showers bring May flowers, but this year they've also brought a bumper crop of grass, ragweed and early-budding trees that means misery to millions of allergic Americans.
ADVERTISEMENT
Experts across the country say they are recording the highest pollen counts they've seen in a decade. And while the Southeast usually gets slammed the hardest when it comes to airborne allergens, this season it may be Yankees who are suffering the most.
"I looked at the total pollen counts for this season compared to last, and, at this point, we have already reached 80-90 percent of what we saw for the entire season last year," said Albany, N.Y.-based allergy specialist Dr. David Shulan, a spokesman for the American Academy of Allergy, Asthma and Immunology (AAAAI).
The culprit: a mild, wet winter and early spring, plus unusually warm days.
"We have seen an early and aggressive allergy season, including seasonal pollens and mold spores," said Dr. Clifford Bassett, a Long Island-based allergist and vice-chairman of AAAAI's Public Education Committee.
Shulan agreed. "The buds have been ready to burst, and when we have these warm days, the pollen counts have been just wild," he said.
According to the Allergy and Asthma Foundation of America, which estimates that 50 million Americans are impacted by allergies, the top 10 worst cities to be in right now, in terms of airborne allergens, are:
* Hartford, Conn.
* Greenville, S.C.
* Boston
* Detroit
* Orlando, Fla.
* Knoxville, Tenn.
* Omaha, Neb.
* Sacramento, Calif.
* Washington, D.C.
* Baltimore
There are steps the allergic can take to minimize the sneezing, wheezing and itchy eyes that plague them this season. One is obvious: Avoid the great outdoors. That doesn't mean sealing yourself indoors 24/7, experts said, but some common-sense tips might help.
"First off, get someone else to help you with yard chores -- find someone in the family who's not allergic to do the mowing, for example," said Dr. Sandra McMahan, a senior staff physician specializing in pediatric allergy at Scott & White Memorial Hospital in Temple, Texas.
Pollen counts are always highest in the morning, so try and plan outdoor activities for the afternoon or evening whenever possible. Rain tends to drive allergens out of the air, so planning activities for just after a good rain makes sense, too. "The patient will frequently feel better for a day or so after a rainstorm, because there's less pollen blowing around," said McMahan, who is also an assistant professor of internal medicine at the Texas A & M Health Science Center College of Medicine.
All the experts stressed that keeping windows closed and using air conditioning -- even when the weather is pleasant outside -- can cut the misery for allergic individuals while they're at home.
But what about that perennial springtime passion, gardening? Bassett said green-thumbed Americans can still enjoy their hobby, despite allergies, as long as they follow a few simple steps.
First off, he said, wear gloves and a pollen mask while outside, and work on relatively humid, windless days. Keep soils moist and gardens free of flowering weeds. Shower and shampoo after you come back inside. Rinse off glasses after gardening and keep gardening clothing away from the bedroom.
Bassett also advised against planting the following high-allergen species: amaranthus, crocus, elderberry, juniper, peony, poppy and privet. Some low-allergen alternatives include azalea, begonia, bougainvillea, daisy, dahlia, gladiola, iris, irish moss, marigold, orchids, snapdragon, sunflowers, tulips, violets and zinnias.
And don't forget the secret sex lives of plants: "Planting female trees in one's own yard will attract and then trap incoming airborne pollen from male plants," Bassett warned.
The experts also advised that people back up all of these tips with medication.
"Medications are much better now than they were in the past," McMahan said. "We have the nonsedating antihistamines, which are very helpful and much safer to use. One -- loratadine, generic Claritin -- is now available over-the-counter." There's also an antihistamine nasal spray, Astelin, available by prescription, he added
Besides these, there are what Shulan called the "heavy hitters" -- nasal steroids such as Flonase (now available in a cheaper generic form) as well as Rhinocort, Nasacort and Nasonex.
"Remember though, these drugs take time to start working -- it make take up to two weeks for them to take full effect, although you'll notice some relief in a day or two," Shulan said. "With the nasal steroids, you have to use them regularly throughout the season," he added
So, with proper planning and the right pharmaceuticals, most Americans should be able to cope with even this year's tough allergy season.
But they may have to be patient.
"Here in Albany, the trees start acting up from late March going into June, then the grass takes over in late May, peaking in June and early July," Shulan said. "That should go right through summer till it tapers off sometime in September."
More information
For much more on seasonal allergies, head to the American Academy of Allergy, Asthma and Immunology.
AVNR getting crushed today... but no news. Anyone have any ideas why?
Urche: This should answer your question. Prehistin will be over the counter...
Cobalis Corp. PreHistin(TM) Approval Process to Be Conducted by OTC Division of FDA
Thursday January 19, 8:00 am ET
FDA's Office of Nonprescription Products Will Now Handle Marketing Approval Process for Anti-Allergy Drug PreHistin(TM)
IRVINE, Calif., Jan. 19 /PRNewswire-FirstCall/ -- Cobalis Corp. (OTC Bulletin Board: CLSC - News), a pharmaceutical development company specializing in anti-allergy medications, announced today that the Company has been notified by the FDA that the marketing approval process (IND) for its anti-allergy product, PreHistin(TM), will now be conducted within the FDA by the Office of Nonprescription Products, the branch of the FDA which handles over-the-counter (OTC) drug products.
ADVERTISEMENT
The Company sees this as a positive development since, as an FDA-approved OTC drug, PreHistin(TM) would not require a doctor's prescription, thus making consumer purchases easier, faster and more convenient. Based on an extensive long-term history of safety, PreHistin(TM) has been intended to be an OTC product from its inception.
Typically, drugs that are approved for OTC marketing in the US are considered safe for consumers to purchase themselves, without requiring a physician's supervision. The market in the US for OTC allergy treatments exceeded $4.6 billion last year.
In regard to the drug approval process for PreHistin(TM), the FDA has also indicated to Cobalis that there is no distinction in the OTC environment between seasonal allergies and year-round allergies. The FDA has further indicated to the Company that it is likely that chronically allergic people would take PreHistin(TM) continuously. Thus, the anticipated indication would include both seasonal and perennial allergies which would increase the potential market for PreHistin(TM) to include not only seasonal allergies (such as hay fever), but year round allergies, such as cat, dog and other pet dander, dust mites, cockroaches and mold.
As previously announced, Cobalis has successfully completed the first of two required large-scale Phase III Clinical Trials, in which PreHistin(TM) demonstrated both clinical and statistical significance in a double-blind, placebo-controlled study of 714 allergy patients. The Company plans to engage the second Phase III Clinical Trial in the late spring of 2006.
Said Chas Radovich, CEO of Cobalis Corp.: "We are very pleased to report yet another major milestone with the news that the approval review for PreHistin(TM) is now officially in the hands of the OTC division at the FDA. Based on the extensive history of safe usage of cyanocobalamin, the primary ingredient of PreHistin(TM), we look forward to a smooth review process and to receiving OTC approval for PreHistin(TM)."
ABOUT COBALIS CORP. - PREHISTIN(TM)
Headquartered in Irvine, California, Cobalis Corp. is an over-the-counter, specialty pharmaceutical company. Its flagship product, PreHistin(TM) is currently in Phase III clinical trials and initial marketing in the U.S. will commence upon final FDA marketing approval. The U.S. anti-allergy medication market was $7.2 billion in 2003 and is expected to exceed $10 billion by 2010. PreHistin(TM), The World's First Pre-Histamine(TM), is currently in Phase III Clinical Trials in preparation for submission to the FDA to gain OTC approval for the allergy indication.
For further information please visit the website at http://www.cobalis.com
Bravo! Foods International Corp. Announces Appointment of New Member to the Board of Directors
Thursday April 6, 8:30 am ET
NORTH PALM BEACH, Fla., April 6 /PRNewswire-FirstCall/ -- Bravo! Foods International Corp. (OTC Bulletin Board: BRVO - News), a brand development and marketing company that manufactures, promotes and distributes vitamin- fortified, flavored milk drinks and other beverages, announced today that it elected Gerald L. Bos to its Board of Directors, bringing the total number of members of its board to seven. Mr. Bos will also be a member of the Audit Committee of the Board.
ADVERTISEMENT
Prior to his retirement on December 31, 2005, Mr. Bos was Chief Financial Officer of Dairy Farmers of America, Inc. (DFA), a cooperative owned and operated by approximately 20,600 dairy farmers. DFA is a diversified US manufacturer of dairy products, food components and ingredients. The cooperative is considered a leader in formulating and packaging shelf-stable dairy products in cans and glass. Mr. Bos will continue to serve DFA in a consulting capacity.
Mr. Bos began his career with the accounting firm of Touche-Ross & Co., holding several key positions during his tenure at the firm. In 1979, he joined Mid-America Dairymen, Inc. (Mid-Am) as Corporate Vice President, Finance and Accounting. Mid-America is one of the predecessor dairy marketing cooperatives that merged to form DFA in 1998. Mr. Bos was promoted to Mid- Am's Chief Financial Officer in 1998 a position he retained until his retirement.
Roy Warren, Chief Executive Officer commented on the appointment, "We are extremely pleased to have Mr. Bos as a Member of our Board of Directors. He has been an invaluable friend and resource for Bravo! over the past few years and we are honored that he has agreed to join our Board. His years of experience in the dairy industry combined with his strong finance and accounting background will serve Bravo! well."
"As I move into the next stage of my career, I am excited to be working with Bravo!," said Jerry Bos. "Having had a close working association with Bravo! Foods over the past several years, I have seen first-hand how the business model has evolved and I look forward to working with Bravo! in my new capacity as a Board member," he added.
Housekeeping Issues
The "Lucky 7" rules of the CLSC board:
1. Discussion supporting this stock is welcome here
2. Discussion against the stock is welcome here
3. Competitive analysis is welcome here
4. Using similar companies as models for comparison is welcome here
5. Personal attacks or bashing are NOT welcome
6. Take other stocks to other boards
7. Hype without any evidence will be treated as SPAM and deleted
Since I travel alot from my job, I am not always able to check the board and do maintenance on these issues. I will do my best to keep on top of things and keep the hype to a minimum.
ScaryStocks
Randy, dont misunderstand. It is OK to go off topic from time to time. I also appreciate the bits on other interesting stocks. But there are limits that we need to watch out for.
I came here to IHub because of the constant BS on the Yahoo and Ragingbull boards. There are boards on Yahoo where you have to go through 20+ messages just to find one with relevant information.
The goal is to maintain a discussion on Cobalis that we can all learn from (and hopefully profit from). So please keep the posts coming.
Scary
OK gang. Let's keep on track here.
So far the board has been tight. But sometimes a few get caried away.
Let's stick to the facts. And debate is always welcome.
New interest on the rise.
Several possible reasons that I can imagine:
1. Second Phase III about to start this Spring.
2. Activity on the Partnership(s) that they are looking to form.
3. Recent mainstream exposure in Men's Journal.
I wish I would have bought more shares at the lower price.
Wow, what a day.
Why the huge volume? Was it the article in Men's Journal? That's my guess.
Good things are on the way.
Some info on migraine and allergies:
http://www.lef.org/magazine/mag2004/abstracts/sep2004_abs_03.htm
http://www.mdheal.org/childhoo.htm
http://www.nutramed.com/headache/migraineref.htm
There is alot out there on the link between the two. Many seem to be related to food allergies.
Conf Call notes were great Randy. The attached link is to the PDF of the presentation for anyone interested. There is also audio available on the Cobalis site.
http://www.cobalis.com/news/cobalis_presentation.pdf
Check out the Biotech Values board for more on YMI.
There are alot of people who follow YMI on that board and you can find alot of great info on other Biotech stocks there.
Also, check the CLSC board for another interesting biotech.
Glad to hear positive info on Prehistin.
Since the CLSC sublingual lozenge it is not yet approved, where did you get it? What form? Pill/Lozenge? Or are you taking B12?
I was in INSM some time ago but took a small loss over time. Perhaps it is time to check back in closer to the GHIS filing. Another one to add to my list of research to do...
Scary
Official Milk of US Club Soccer for 2006
http://biz.yahoo.com/prnews/060222/flw005.html?.v=46
Randy, Thanks for the info on CLSC.
I saw your posts on the Yahoo YMI board about GMED.pk
After some DD on GMED, I wouldn't think this a smart move. My concern is the "limited" size of their trails. (I didn't think it was possible to have a trail with 1 patient.) My advice would be to get out.
Your posts here and on YMI have been appreciated. Any other good leads our friends here at the CLSC board can look into??? (Don't worry. I have a background in the Biotech industry and will ALWAYS do my own DD. Any suggestions will be taken as a starting place to begin research)
Scary
YMI really starting to move. Up 6.4% today.
Alot of potential good news in 2006.
Roth Capital Partners Conference
http://biz.yahoo.com/prnews/060217/flf004.html?.v=44
Recovery after $9.5 million share offering
http://biz.yahoo.com/ap/060214/ym_biosciences_offering.html?.v=1
I got in at 4.50 per share. YMI seems to have recovered quickly from the offering at 4.25... too much good news ahead. IMO.
Scary
Form 10QSB from 2/14/06
http://biz.yahoo.com/e/060214/clsc.ob10qsb.html
I haven't read through it yet, but will later. Comments welcome...
Let's review...
Since the next part of the Phase III won't start until April (allergy season), I am looking at some of the earlier data. This will give a good benchmark for the next round of results.
http://www.biogentec.com/news/news_19.pdf#search='Cobalis%20Corp.'
Time to stock up on beer and snacks for the big snowstorm on the way here in the North East.
Good luck to all.
Scary
CLSC- 50K purchase from James Hammer on Yahoo Insider Section
http://finance.yahoo.com/q/it?s=CLSC.OB
Good move up today.
Randy, I don't think we can charge a fee for Marty's comments. He hasn't posted in about a month.
My guess is that they are playing it safe and any comments from the company will be in official press releases from now on.
But his comments are always welcome and very much appreciated if he decides to post again.
I have been long on Avanir for about 3 years. Let me just say that Dr. Yakatan was not well liked on some of the Avanir boards. (And I am being kind here.)
On the positive side, his experience with bringing Abreva to market may help.
Let's wait and see...
Scary
Thanks for the suggestion Randy. As time allows I will add features like that to the board. This week I added a few pics. So it is coming along... hey we just passed 100 posts. Not bad.
Thanks Randy and Urche.
I appreciate the feedback on Nastech. It is always a good idea to keep an eye out on any potential competition. This type of information is always welcome on this board.
Also, thanks for the summary of potential milestones for 2006. I agree, there is a great potential for positive milestones to be met.
Scary
Marty,
I recently found information on a nasal spray of Cyanocobalamin called Nascobal from Questcor.
General web site
http://www.nascobal.com/index.html
Prescribing info
http://www.nascobal.com/prescr_info.html
Is there any potential there for a competitive product?
Thanks in advance.
ScaryStocks
Randy, thanks for the great info.
Have you heard anything from Marty recently? I know the next part of the phase III won't start until Spring. But perhaps some news on any partnerships? (Financing in '06 is one of my concerns)
Positive news would be great to keep the pps from slipping further.
This is a postential blockbuster product... good luck to all.
ScaryStocks
Thanks for all of the detailed DD on Cobalis, Randy. A colleague of mine and I are still learning about this company and doing our homework. So the info you post is greatly appreciated.
I will be away on business for the next 6 days. But I hope to catch up on some of this research when I get back next week.
Best of luck to all.